Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis.

Kuchimanchi, Mita; Bockbrader, Howard; Dolphin, Nancy; Epling, Daniel; Quinlan, Lauren; Chapel, Sunny; Penner, Natasha

Kuchimanchi, Mita; Bockbrader, Howard; Dolphin, Nancy; Epling, Daniel; Quinlan, Lauren; Chapel, Sunny; Penner, Natasha.

Afiliação

Kuchimanchi M; Biogen, Cambridge, MA, USA.
Bockbrader H; Ann Arbor Pharmacometrics Group (A2PG), Ann Arbor, MI, USA.
Dolphin N; Ann Arbor Pharmacometrics Group (A2PG), Ann Arbor, MI, USA.
Epling D; Ann Arbor Pharmacometrics Group (A2PG), Ann Arbor, MI, USA.
Quinlan L; Ann Arbor Pharmacometrics Group (A2PG), Ann Arbor, MI, USA.
Chapel S; Ann Arbor Pharmacometrics Group (A2PG), Ann Arbor, MI, USA.
Penner N; Biogen, Cambridge, MA, USA. natalia.penner@gmail.com.

Neurol Ther ; 11(1): 353-371, 2022 Mar.

Article em En | MEDLINE | ID: mdl-35041178

Palavras-chave

2-Hydroxyethyl succinimide; Diroximel fumarate; Monomethyl fumarate; Multiple sclerosis; Pharmacokinetics; Population pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Neurol Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google